Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of OTX-2002 As a Single Agent and in Combination with Standard of Care in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

NCT05497453 is registered in ClinicalTrials.gov with Omega Therapeutics as lead sponsor.

NCT NCT05497453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05497453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of OTX-2002 As a Single Agent and in Combination with Standard of Care in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
Lead sponsor
Omega Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
August 19, 2022
Completion date
November 21, 2024
Enrollment
24 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer, hepatocellular carcinoma, hepatocellular carcinoma non-resectable, hepatocellular carcinoma recurrent, liver cancer, liver, cancer of, non-resectable, solid tumor